Ubs Group Ag Gt Biopharma, Inc. Transaction History

Ubs Group Ag

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.22 - $0.28 $1,288 - $1,639	5,855 Added 66.91%	14,605 $3,000
Q3 2023 Nov 09, 2023	BUY	$0.24 - $0.35 $1,372 - $2,000	5,717 Added 188.49%	8,750 $2,000
Q2 2023 Aug 11, 2023	SELL	$0.22 - $0.55 $1,047 - $2,618	-4,760 Reduced 61.08%	3,033 $0
Q1 2023 May 12, 2023	BUY	$0.46 - $1.05 $1,964 - $4,483	4,270 Added 121.2%	7,793 $4,000
Q4 2022 Feb 08, 2023	BUY	$0.89 - $58.2 $314 - $20,544	353 Added 11.14%	3,523 $3,000
Q3 2022 Nov 10, 2022	BUY	$1.81 - $56.1 $97 - $3,029	54 Added 1.73%	3,170 $5,000
Q2 2022 Aug 10, 2022	SELL	$1.64 - $3.11 $2,107 - $3,996	-1,285 Reduced 29.2%	3,116 $9,000
Q1 2022 May 16, 2022	SELL	$2.6 - $3.3 $18,311 - $23,241	-7,043 Reduced 61.54%	4,401 $13,000
Q4 2021 Feb 14, 2022	BUY	$3.05 - $7.08 $20,392 - $47,336	6,686 Added 140.52%	11,444 $34,000
Q3 2021 Nov 15, 2021	BUY	$6.68 - $15.26 $11,055 - $25,255	1,655 Added 53.34%	4,758 $32,000
Q2 2021 Aug 13, 2021	SELL	$7.19 - $18.96 $5,859 - $15,452	-815 Reduced 20.8%	3,103 $48,000
Q1 2021 May 12, 2021	BUY	$4.4 - $8.84 $17,239 - $34,635	3,918 New	3,918 $27,000

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $81.7M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.